• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Post Hoc Analyses of Randomized Clinical Trial for the Effect of Clopidogrel Added to Aspirin on Kidney Function.
CONCLUSIONS: We found no effect of clopidogrel added to aspirin compared with aspirin alone on kidney function decline among persons with prior lacunar stroke. PMID: 28446537 [PubMed - as supplied by publisher]
Source: Clinical Journal of the American Society of Nephrology : CJASN - April 26, 2017 Category: Urology & Nephrology Authors: Ikeme JC, Pergola PE, Scherzer R, Shlipak MG, Benavente OR, Peralta CA Tags: Clin J Am Soc Nephrol Source Type: research

Prasugrel and Ticagrelor in Patients with Drug-Eluting Stents and Kidney Failure
CONCLUSIONS: Prasugrel or ticagrelor does not seem to be associated with significant benefits compared with clopidogrel in patients with kidney failure treated with drug-eluting stents.PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2021_04_02_CJN12120720.mp3.PMID:33811128 | DOI:10.2215/CJN.12120720
Source: Clinical Journal of the American Society of Nephrology : CJASN - April 3, 2021 Category: Urology & Nephrology Authors: Thomas A Mavrakanas Omer Kamal David M Charytan Source Type: research

Clopidogrel Use in End-Stage Kidney Disease.
In conclusion, current evidence suggests that ESKD patients may not derive the same benefits from clopidogrel therapy as the general population and this therapy may be associated with harm. Properly designed observational studies and randomized controlled trials are needed to establish the role of clopidogrel in patients with ESKD, the use of platelet assays to tailor therapy, and the role of other antiplatelet agents such as prasugrel or ticagrelor in patients who exhibit high on-treatment residual platelet reactivity. PMID: 25476742 [PubMed - as supplied by publisher]
Source: Seminars in Dialysis - December 5, 2014 Category: Urology & Nephrology Authors: Tanios BY, Itani HS, Zimmerman DL Tags: Semin Dial Source Type: research

Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease
Scarce and conflicting evidence exists on whether clopidogrel is effective and whether dual antiplatelet treatment (DAPT) is safe in patients with acute coronary syndrome and chronic kidney disease (CKD). To study this, we performed an observational, prospective, multicenter cohort study of 36,001 patients of the SWEDEHEART registry. The exposure was DAPT prolonged after 3 months versus DAPT stopped at 3 months in consecutive patients with acute coronary syndrome and known serum creatinine. DAPT duration with clopidogrel and aspirin was assessed by dispensed tablets.
Source: Kidney International - November 15, 2016 Category: Urology & Nephrology Authors: Juan-Jesus Carrero, Christoph Varenhorst, Karin Jensevik, Karolina Szummer, Bo Lagerqvist, Marie Evans, Jonas Spaak, Claes Held, Stefan James, Tomas Jernberg Tags: Clinical Investigation Source Type: research

Antiplatelet agents in hemodialysis.
In conclusion, since CRF patients are one of the groups at highest risk for atherosclerotic events, it could be reasonable to use aspirin in HD patients. However, the bleeding risk in HD patients needs to be strongly evaluated, especially before starting dual AA treatment. PMID: 27928736 [PubMed - as supplied by publisher]
Source: Journal of Nephrology - December 7, 2016 Category: Urology & Nephrology Authors: Migliori M, Cantaluppi V, Scatena A, Panichi V Tags: J Nephrol Source Type: research